BriaCell Therapeutics Corp., a biotech firm focused on developing new treatments for cancer, recently shared promising results from their studies on breast cancer treatments. Here’s a breakdown of the key points in plain English:
In a Phase 2 study, 61% of patients with advanced breast cancer saw their disease either stabilize or improve after being treated with BriaCell’s Bria-IMT therapy. This therapy is also being used in a larger, Phase 3 study. For patients who had previously not responded to a specific cancer drug therapy known as antibody-drug conjugate (ADC) therapy, 50% experienced disease control with the Bria-IMT treatment.
The company highlights a notable case: A patient who had not benefited from four earlier treatments, including ADC therapy, and had cancer spread to her liver, saw remarkable improvement with Bria-IMT. After treatment, scans showed that the cancer in her liver was no longer detectable. This patient also experienced a significant delay in the progression of her cancer compared to her previous treatments.
BriaCell’s treatment has shown to be safe, with no patients stopping the therapy due to severe side effects. Importantly, it didn’t cause a dangerous lung condition often seen with other ADC therapies. The treatments have shown to extend the time patients live without their cancer getting worse and offer a better quality of life for those with advanced breast cancer, a group of patients who typically have limited time left.
These results are encouraging, especially for patients who have tried many other treatments without success. BriaCell is continuing its Phase 3 study, aiming to provide more data and potentially a new treatment option for advanced metastatic breast cancer.
BriaCell’s research is showing that their Bria-IMT™ regimen could be a significant new option for treating advanced breast cancer, offering hope to patients who have few other options. The company plans to provide more updates as their studies progress.